Grace Therapeutics’ (GRCE) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Grace Therapeutics (NASDAQ:GRCE) in a research note published on Tuesday morning,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright also issued estimates for Grace Therapeutics’ Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $1.68 EPS.

Grace Therapeutics Stock Performance

Shares of NASDAQ GRCE opened at $3.39 on Tuesday. The firm has a market capitalization of $34.37 million, a price-to-earnings ratio of -2.92 and a beta of 1.36. Grace Therapeutics has a 1 year low of $2.13 and a 1 year high of $4.97. The stock’s 50 day moving average price is $3.65.

Grace Therapeutics (NASDAQ:GRCE) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. Analysts anticipate that Grace Therapeutics will post -0.98 EPS for the current fiscal year.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.